SeaStar Medical(NASDAQ) ICUCW

SeaStar Medical Holding Corporation is a medical device company based in Denver, Colorado, focused on developing innovative therapies to combat hyperinflammation and cytokine storms in critically ill patients. The company specializes in extracorporeal treatments targeting immune effector cells that drive systemic inflammation, leading to tissue damage and dysregulated immune responses.

Products and Services

• Extracorporeal therapies for acute kidney injury in pediatric and adult patients
• Solutions for cardiorenal syndrome in congestive heart failure cases
• Innovative treatments for hepatorenal syndrome and myocardial stunning

Growth Outlook

• Expansion into diverse therapeutic domains enhances market potential
• Increasing demand for innovative treatments in critical care settings
• Strong focus on research and development to drive future product offerings

Financial Highlights

• Q2 2026 revenue of $615,000, up from $495,000 in Q1 2026
• Gross profit margin of 91.22% in Q2 2026 indicates strong product demand
• Cash reserves of $6.96 million as of June 30, 2026, supporting operational needs

SeaStar Medical is positioned in a growing sector of the healthcare industry, with a focus on addressing critical health challenges through innovative medical solutions. The company's commitment to research and development is expected to drive future growth, particularly as the demand for effective treatments in critical care environments continues to rise. Recent financial performance shows a positive trend in revenue, indicating potential for further expansion and market penetration. With a solid cash position, SeaStar Medical is well-equipped to navigate the challenges of the biotechnology landscape while pursuing its mission to improve patient outcomes.